AZ To Adopt Indication-Based Pricing For Farxiga In Heart Failure
As FDA Adds Major Approval To Diabetes Drug's Label
AstraZeneca's biopharmaceuticals president Ruud Dobber tells Scrip that the price for Farxiga in the heart failure indication should reflect its potential to improve survival and reduce the need for hospitalization.
